Stallergenes Greer Ltd, a leading player in the immunotherapy industry, is headquartered in Great Britain and operates extensively across Europe and North America. Founded in 2014 through the merger of Stallergenes and Greer Laboratories, the company has quickly established itself as a pioneer in allergy treatment solutions. Specialising in allergen immunotherapy, Stallergenes Greer offers a range of innovative products, including sublingual and injectable therapies, designed to provide long-term relief from allergic conditions. Their commitment to research and development has led to significant advancements in personalised treatment options, setting them apart in a competitive market. With a strong focus on patient-centric care, Stallergenes Greer Ltd has achieved notable recognition for its contributions to allergy management, solidifying its position as a trusted name in the field.
How does Stallergenes Greer Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Stallergenes Greer Ltd's score of 26 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Stallergenes Greer Ltd, headquartered in Great Britain, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges available at this time. As a result, the company appears to be in the early stages of establishing its climate commitments and emissions reduction strategies. Without specific data or targets, it is challenging to assess their current environmental impact or future commitments in relation to industry standards. In the context of the broader industry, many companies are increasingly adopting Science-Based Targets Initiative (SBTi) guidelines and committing to net-zero emissions. However, Stallergenes Greer Ltd has not yet disclosed any such initiatives or commitments.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Stallergenes Greer Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

